Time to reposition sulfonylureas in type 2 diabetes management in Indian context: A pragmatic practical approach

Sulfonylureas (SU) continue to be a vital therapeutic category of oral hypoglycemic agents (OHAs) for the management of type 2 diabetes mellitus (T2DM). Physicians consider modern SU (gliclazide and glimepiride) as “safe and smart” choices for T2DM management. The presence of multiple international...

Descripción completa

Detalles Bibliográficos
Autores principales: Das, Ashok Kumar, Saboo, Banshi, Chawla, Rajeev, Aravind, S. R., Rajput, Rajesh, Singh, Awadhesh K., Mukherjee, J. J., Jhingan, Ashok, Shah, Parag, Deshmukh, Vaishali, Kale, Shailaja, Jaggi, Shalini, Sridhar, G. R., Dhediya, Rajnish, Gaurav, Kumar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer India 2023
Materias:
Guidelines
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10113130/
https://www.ncbi.nlm.nih.gov/pubmed/37360324
http://dx.doi.org/10.1007/s13410-023-01192-6
Descripción
Sumario:Sulfonylureas (SU) continue to be a vital therapeutic category of oral hypoglycemic agents (OHAs) for the management of type 2 diabetes mellitus (T2DM). Physicians consider modern SU (gliclazide and glimepiride) as “safe and smart” choices for T2DM management. The presence of multiple international guidelines and scarcity of a national guideline may contribute to the challenges faced by few physicians in choosing the right therapeutic strategy. The role of SU in diabetes management is explicit, and the present consensus aims to emphasize the benefits and reposition SU in India. This pragmatic, practical approach aims to define expert recommendations for the physicians to improve caregivers’ knowledge of the management of T2DM, leading to superior patient outcomes.

Ejemplares similares